JP2019509354A5 - - Google Patents

Download PDF

Info

Publication number
JP2019509354A5
JP2019509354A5 JP2019500752A JP2019500752A JP2019509354A5 JP 2019509354 A5 JP2019509354 A5 JP 2019509354A5 JP 2019500752 A JP2019500752 A JP 2019500752A JP 2019500752 A JP2019500752 A JP 2019500752A JP 2019509354 A5 JP2019509354 A5 JP 2019509354A5
Authority
JP
Japan
Prior art keywords
cancer
tumor
cell
inhibitor
lymphoma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019500752A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019509354A (ja
JP7026299B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/023965 external-priority patent/WO2017165732A1/en
Publication of JP2019509354A publication Critical patent/JP2019509354A/ja
Publication of JP2019509354A5 publication Critical patent/JP2019509354A5/ja
Priority to JP2022004776A priority Critical patent/JP7459149B2/ja
Application granted granted Critical
Publication of JP7026299B2 publication Critical patent/JP7026299B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019500752A 2016-03-24 2017-03-24 Tg02によるがん治療 Active JP7026299B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022004776A JP7459149B2 (ja) 2016-03-24 2022-01-17 Tg02によるがん治療

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662312712P 2016-03-24 2016-03-24
US62/312,712 2016-03-24
US201662423468P 2016-11-17 2016-11-17
US62/423,468 2016-11-17
PCT/US2017/023965 WO2017165732A1 (en) 2016-03-24 2017-03-24 Treatment of cancer with tg02

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022004776A Division JP7459149B2 (ja) 2016-03-24 2022-01-17 Tg02によるがん治療

Publications (3)

Publication Number Publication Date
JP2019509354A JP2019509354A (ja) 2019-04-04
JP2019509354A5 true JP2019509354A5 (cg-RX-API-DMAC7.html) 2020-05-07
JP7026299B2 JP7026299B2 (ja) 2022-02-28

Family

ID=59899752

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019500752A Active JP7026299B2 (ja) 2016-03-24 2017-03-24 Tg02によるがん治療
JP2022004776A Active JP7459149B2 (ja) 2016-03-24 2022-01-17 Tg02によるがん治療

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022004776A Active JP7459149B2 (ja) 2016-03-24 2022-01-17 Tg02によるがん治療

Country Status (12)

Country Link
US (2) US11865116B2 (cg-RX-API-DMAC7.html)
EP (1) EP3432888B1 (cg-RX-API-DMAC7.html)
JP (2) JP7026299B2 (cg-RX-API-DMAC7.html)
KR (2) KR102491013B1 (cg-RX-API-DMAC7.html)
CN (2) CN115969854B (cg-RX-API-DMAC7.html)
AU (1) AU2017238647B2 (cg-RX-API-DMAC7.html)
ES (1) ES2941687T3 (cg-RX-API-DMAC7.html)
IL (1) IL261959B2 (cg-RX-API-DMAC7.html)
MX (3) MX2021012977A (cg-RX-API-DMAC7.html)
RU (1) RU2749025C2 (cg-RX-API-DMAC7.html)
SG (2) SG10202005621WA (cg-RX-API-DMAC7.html)
WO (1) WO2017165732A1 (cg-RX-API-DMAC7.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230133934A (ko) 2016-10-11 2023-09-19 아게누스 인코포레이티드 항-lag-3 항체 및 이의 사용 방법
WO2019032628A1 (en) 2017-08-07 2019-02-14 The Regents Of The University Of California GENERATING PLATFORM FOR SAFE CELLULAR THERAPEUTIC AGENTS
ES2977589T3 (es) 2017-08-18 2024-08-27 Cothera Bioscience Inc Forma polimórfica de TG02
MX2021011301A (es) * 2019-03-18 2022-01-19 Univ Texas Terapia combinada especifica contra tumores.
ES3034869T3 (en) * 2019-04-22 2025-08-25 Univ Pittsburgh Commonwealth Sys Higher Education Tg02 for use in treating gliomas in pediatric subjects
WO2021155580A1 (en) * 2020-02-07 2021-08-12 Cothera Bioscience, Inc. Combination therapies and biomarkers for treating cancer
US12264190B2 (en) * 2020-04-24 2025-04-01 Astrazeneca Ab Compositions and methods of treating cancer with chimeric antigen receptors
WO2022035723A1 (en) * 2020-08-10 2022-02-17 The Broad Institute, Inc. Compositions, panels, and methods for characterizing chronic lymphocytic leukemia
MX2024006078A (es) * 2021-11-18 2024-08-09 Lantern Pharma Inc Metodo para tratar el cancer con acilfulveno y radiacion.
CN114113051B (zh) * 2021-12-16 2023-06-16 南京信息工程大学 一种psma电致化学发光传感器的制备方法及应用
EP4197525A1 (en) 2021-12-20 2023-06-21 Scandion Oncology A/S Combination of drugs for the treatment of cancer
CN114480639B (zh) * 2021-12-24 2022-09-30 中国医学科学院北京协和医院 新靶点用于诊断和治疗垂体腺瘤
WO2023143608A1 (zh) * 2022-01-30 2023-08-03 上海复东生物医药有限责任公司 一种组合物、其制备方法及应用
CN114518456B (zh) * 2022-02-17 2025-06-20 南京医科大学 一种通过diaph1蛋白预测肿瘤免疫治疗疗效的方法及试剂盒
WO2023242235A1 (en) 2022-06-14 2023-12-21 Scandion Oncology A/S Abcg2 inhibitor and nae inhibitor for the treatment of cancer
CN115429793A (zh) * 2022-08-15 2022-12-06 复旦大学附属中山医院 一种化合物在制备治疗肝细胞癌药物中的应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR8108820A (pt) 1980-09-24 1982-08-24 Cetus Corp Processo e sonda de diagnostico
US4582788A (en) 1982-01-22 1986-04-15 Cetus Corporation HLA typing method and cDNA probes used therein
EP0084796B1 (en) 1982-01-22 1990-05-02 Cetus Corporation Hla typing method and cdna probes used therein
US4683194A (en) 1984-05-29 1987-07-28 Cetus Corporation Method for detection of polymorphic restriction sites and nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
CA1284931C (en) 1986-03-13 1991-06-18 Henry A. Erlich Process for detecting specific nucleotide variations and genetic polymorphisms present in nucleic acids
CA1338457C (en) 1986-08-22 1996-07-16 Henry A. Erlich Purified thermostable enzyme
US6605712B1 (en) 1990-12-20 2003-08-12 Arch Development Corporation Gene transcription and ionizing radiation: methods and compositions
CN101360751B (zh) 2005-11-16 2011-09-14 S*Bio私人有限公司 氧连接的嘧啶衍生物
US9120815B2 (en) * 2010-02-05 2015-09-01 Tragara Pharmaceuticals, Inc. Solid state forms of macrocyclic kinase inhibitors
WO2014011695A2 (en) * 2012-07-09 2014-01-16 Onyx Therapeutics, Inc. Prodrugs of peptide epoxy ketone protease inhibitors
WO2014161046A1 (en) * 2013-04-04 2014-10-09 The Walter And Eliza Hall Institute Of Medical Research Methods of treating diseases characterized by excessive wnt signalling
CN105473581B (zh) * 2013-06-21 2019-04-23 齐尼思表观遗传学有限公司 作为溴结构域抑制剂的新取代的双环化合物
AU2014309199B2 (en) 2013-08-20 2018-04-19 Merck Sharp & Dohme Llc Treating cancer with a combination of a PD-1 antagonist and dinaciclib
US11013743B2 (en) * 2013-12-20 2021-05-25 Biomed Valley Discoveries, Inc. Cancer treatments using combinations of CDK and ERK inhibitors
US10383873B2 (en) * 2014-04-04 2019-08-20 Memorial Sloan-Kettering Cancer Center Method and kits for identifying of CDK9 inhibitors for the treatment of cancer
JP6767875B2 (ja) 2014-04-08 2020-10-14 ライジェル ファーマシューティカルズ, インコーポレイテッド Tgf−ベータ阻害剤としての2,3−二置換ピリジン化合物および使用方法
EP3191126B1 (en) 2014-09-13 2020-05-13 Novartis AG Combination therapies of alk inhibitors
ES2977589T3 (es) 2017-08-18 2024-08-27 Cothera Bioscience Inc Forma polimórfica de TG02

Similar Documents

Publication Publication Date Title
Halder et al. Targeting the EGFR signaling pathway in cancer therapy: What’s new in 2023?
Malhotra et al. Phase Ib/II study of hydroxychloroquine in combination with chemotherapy in patients with metastatic non-small cell lung cancer (NSCLC)
Yang et al. RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models
Hussain et al. Cancer drug resistance: A fleet to conquer
Mross et al. A phase I dose–escalation study of regorafenib (BAY 73–4506), an inhibitor of oncogenic, angiogenic, and stromal kinases, in patients with advanced solid tumors
Del Vecchio et al. Efficacy and safety of ipilimumab 3 mg/kg in patients with pretreated, metastatic, mucosal melanoma
Sohal et al. A phase II trial of gemcitabine, irinotecan and panitumumab in advanced cholangiocarcinoma
ES3055185T3 (en) Treatment of an estrogen receptor positive breast cancer using a selective estrogen receptor modulator
RU2018137217A (ru) Лечение рака при помощи tg02
Sastre et al. First-line single-agent panitumumab in frail elderly patients with wild-type KRAS metastatic colorectal cancer and poor prognostic factors: a phase II study of the Spanish Cooperative Group for the Treatment of Digestive Tumours
Panagi et al. Stabilizing tumor-resident mast cells restores T-cell infiltration and sensitizes sarcomas to PD-L1 inhibition
Quinn et al. Therapeutic inhibition of the receptor tyrosine kinase AXL improves sensitivity to platinum and taxane in ovarian cancer
Shi et al. Identifying TOPK and hypoxia hallmarks in esophageal tumors for photodynamic/chemo/immunotherapy and liver metastasis inhibition with nanocarriers
Yoshioka et al. Efficacy and safety of erlotinib in elderly patients in the phase IV POLARSTAR surveillance study of Japanese patients with non-small-cell lung cancer
Chiang et al. Regorafenib enhances antitumor immune efficacy of anti-PD-L1 immunotherapy on oral squamous cell carcinoma
RU2764175C1 (ru) Бифункциональные композиции для лечения рака
IL272697B2 (en) A polymorphic form of TG02
US20200093815A1 (en) Combinations of ezh2 inhibitors with further agents for use in the treatment of cancer
TW201625304A (zh) 泌尿上皮癌之療法
Alrosan et al. Treatment of ovarian cancer: From the past to the new era
Gainor et al. A phase II study of the multikinase inhibitor ponatinib in patients with advanced, RET-rearranged NSCLC
Mahmood et al. An enhanced chemopreventive effect of methyl donor S-adenosylmethionine in combination with 25-hydroxyvitamin D in blocking mammary tumor growth and metastasis
WO2018138510A1 (en) Mebendazole for use in the treatment of cancer
Bulut et al. Metabolic syndrome prevalence in renal cell cancer patients
Li et al. Apatinib for chemotherapy-refractory extensive-stage SCLC: a retrospective study